LC-400

ULTRA LONG ACTING LOCAL ANESTHETICS – ULALA

Implementation of LipoCure’s unique liposomal encapsulation drug delivery approach allows for the development of more efficient anesthetics with a prolonged analgesia effect due to slower release, higher API concentration, lower toxicity, and reduced side effects. Current results demonstrate a t1/2 >12 hours compared to 1 hour in mice, and t1/2 >40 hours compared to 2 hours in humans – tenfold longer-lasting analgesia effects!

The company is currently studying a liposome-encapsulated bupivacaine formulation comprised of large and multi-vesicular vesicles (LMVV) that have an exceptionally large aqueous trapped volume of more than 10l/ml, allowing for a much higher drug-to-lipid ratio.